Micromet Reacquires Full North American Rights To Blinatumomab
This article was originally published in The Pink Sheet Daily
Executive Summary
Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.
You may also be interested in...
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
Micromet Gets $14M Upfront From Amgen For BiTE Technology
The world's largest biotech is investing in the research of BiTE antibodies against three undisclosed solid tumor targets.
Micromet Gets $14M Upfront From Amgen For BiTE Technology
The world's largest biotech is investing in the research of BiTE antibodies against three undisclosed solid tumor targets.